Navigation Links
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Date:5/28/2008

ilable by spring 2009.

-- Planned filing of global marketing authorization applications by fall

2009.

Also in 2008, Novartis plans to initiate a Phase 2 trial to evaluate monthly dosing of Albuferon in treatment-nave patients with genotypes 2 and 3 chronic hepatitis C.

LymphoStat-B(R) (belimumab), a human monoclonal antibody that neutralizes BLyS(TM) (B-lymphocyte stimulator), for the treatment of systemic lupus erythematosus SLE

In November 2007, Phase 2 results were presented at the Annual Scientific Meeting of the American College of Rheumatology, which demonstrated that LymphoStat-B achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was generally well tolerated through 2.5 years on treatment in combination with standard of care in patients with active SLE. The results through 2.5 years confirm and extend the data presented at previous scientific meetings at earlier time points, including a significant reduction in SLE disease activity as measured by the response rate chosen as the primary efficacy endpoint of the Phase 3 trials. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Recent progress: In April 2008, HGS completed enrollment and initial dosing in BLISS-52, one of two pivotal Phase 3 clinical trials of LymphoStat-B in patients with active SLE. Completion of enrollment for the other pivotal Phase 3 trial, BLISS-76, is expected by the end of summer 2008. The LymphoStat-B BLISS program is the only Phase 3 program in SLE with a protocol design informed by prior randomized data.

Today's therapy for SLE patients involves a variety of immunosuppressive and cytotoxic agents, with prednisone as the mainstay. These existing treatments are generally considered inadequate because of their significant side effects and their inability to adequatel
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 ABIVAX, a clinical ... vaccines, today announced that it has dosed in ... IIb/III clinical trial of ABX203 which is taking place in ... The study is designed to assess whether ABX203 can deliver ... (CHB) via controlling viral load for a much longer period ...
(Date:2/26/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... million for the fourth quarter ended December 31, 2014, ... for the same period of 2013.  For the fiscal ... a 34% increase compared to revenue of $207.9 million ...
(Date:2/26/2015)... 26, 2015  Caris Life Sciences® today announced ... Genitourinary Cancers Symposium in Orlando, Fla. ... the Audio Poster Tour. Both studies utilized Caris ... service. These studies showed that panomic testing can ... carcinomas (RCC), providing insights that may drive selection ...
Breaking Medicine Technology:ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 2ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 3ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 4ABIVAX Recruits First Patient in a Pivotal Phase IIb/III Clinical Trial with ABX203, a Novel Immunotherapy Against Chronic Hepatitis B 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 2HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 3HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 4HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 5HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 6HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 7HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 8HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 9HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 10HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 11HeartWare International Reports $73.2 Million In Fourth Quarter 2014 Revenue; 38% Increase From Fourth Quarter 2013 12Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 2Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 3Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 4Caris Life Sciences' Multiplatform Tumor Profiling Helps to Identify Potential Predictive Biomarkers in Renal Cell Carcinoma 5
... DATA ), a technology and services company focused ... reported its,operating results for the first quarter of 2008., ... revenue decreased,approximately 41% to $2,088,000 and the Company reported ... both a basic and diluted basis. These,results compared with ...
... data support potential of asenapine in the treatment of ... schizophrenia and bipolar I ... ) today announced that an overview of asenapine clinical trials,from ... of the,American Psychiatric Association in Washington, D.C., May 3-8. Data ...
Cached Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7
(Date:2/26/2015)... 2015 Deep Market Research Report on ... study on the current state of the global ... the Chinese situation. , Major companies included in ... Hu-Friedy, Medisporex, Towne Brothers, Teleflex Medical, Landanger, YDM, ... Equipment, Shuanglu, Changshu Henry Medical Instrument, and Kangqiao ...
(Date:2/26/2015)... 2015 “ KnowNote ” was featured on ... latest and coolest mobile applications on the iOS, Android, and ... of NewsWatch, conducted the app review and shared with viewers ... rhythm and in tune. , Learning a musical instrument can ... what if people could take something they already know and ...
(Date:2/26/2015)... Claflin Medical Equipment , a Rhode Island based medical ... based medical equipment distributor, have announced a merger effective ... premier organizations that specialize in equipment and the logistics ... By combining forces, they can now cover the entire ... Claflin will gain even greater reach with their government ...
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... Chairman J. Robert Baum, Ph.D. is stepping down as ... succeeded by Joseph C. Guyaux, senior vice chairman of ... chief executive officer, PNC Mortgage. Additionally, Highmark Health President ... the chairman of the board of directors of Highmark ...
(Date:2/26/2015)... 26, 2015 Growth in the ... by a EuroMonitor International Report that U.S. men’s ... In response to the robust demand for ... launching a barbering program in partnership with internationally ... Factory” salon. The proprietary curriculum features 10 signature ...
Breaking Medicine News(10 mins):Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 2Health News:Global Hemostat Industry Data, Size and Growth Report 2015-2020 Now Available at DeepResearchReports.com 3Health News:A Modern Way to Learn Music was Featured on NewsWatch Television on January 30, 2015 2Health News:Claflin Medical Equipment Announces Merger with Hospital Associates 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 2Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 3Health News:Highmark Health Appoints Joseph C. Guyaux Chairman of the Board of Directors 4Health News:Bellus Academy Partners with Renowned Hairstylist D.J. Muldoon to Launch Signature Barbering Program 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... PalmScan P2000 Pachymeter [i.e., PalmScan P2000] ... operated biometer, which incorporates A-mode pulsed-echo ... to accurately measure the corneal thickness ... eyes. PalmScan P2000 includes two software ...
... PalmScan A2000 A-Scan [i.e., PalmScan A2000] device ... which incorporates A-mode pulsed-echo ultrasound,technology, and thus ... axial length (AL), anterior,chamber depth (ACD), and ... PalmScan A2000,device is also intended for calculating ...
... low TLR (<1%) and stroke rate - ... long-term durability., , , High Radial Strength: ... artery, increasing lumen diameter with chronic outward ... stent shortening, low profile design, Cordis TRUMARK™ ...
Medicine Products: